Premium
Combination of the anti‐CD30‐auristatin‐E antibody‐drug conjugate (SGN‐35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
Author(s) -
Oflazoglu Ezogelin,
Kissler Kim M.,
Sievers Eric L.,
Grewal Iqbal S.,
Gerber HansPeter
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07146.x
Subject(s) - brentuximab vedotin , vinblastine , bleomycin , dacarbazine , medicine , antibody drug conjugate , abvd , lymphoma , cd30 , chemotherapy , doxorubicin , cancer research , gemcitabine , conjugate , monoclonal antibody , anaplastic large cell lymphoma , pharmacology , oncology , vincristine , antibody , immunology , cyclophosphamide , mathematical analysis , mathematics
Summary The antibody‐drug conjugate (ADC) cAC10‐vcMMAE consists of the tubulin inhibitor monomethyl auristatin E (MMAE) conjugated to the chimeric anti‐CD30 monoclonal antibody cAC10. This ADC potently interferes with the growth of CD30‐positive haematological tumours, including Hodgkin lymphoma (HL) and anaplastic large‐cell lymphoma. This study found improved antitumour activity in a preclinical model of HL when SGN‐35 was combined with chemotherapeutic regimens such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or gemcitabine. Improved efficacy was also observed in high tumour burden models, indicating that combining ADCs with chemotherapeutic agents may be advantageous for the treatment of patients with relapsed or refractory HL.